Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3418)
All Articles published online
|
Publishing Process of This Article
|
Jun 16, 2022 (publication date) through Dec 20, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Li QY, Lv Y, An ZY, Dai NN, Hong X, Zhang Y, Liang LJ. Ethical review of off-label drugs during the COVID-19 pandemic. World J Clin Cases 2022; 10(17): 5541-5550 [PMID: 35979109 DOI: 10.12998/wjcc.v10.i17.5541] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i17/5541.htm |
| Number | Citing Articles |
| 1 |
Daniel Furtner, Gabor Hutas, Bryan Jie Wen Tan, Roland Meier. Journey from an Enabler to a Strategic Leader: Integration of the Medical Affairs Function in ESG Initiatives and Values. Pharmaceutical Medicine 2023; 37(6): 405 doi: 10.1007/s40290-023-00485-9
|
| 2 |
S. V. Russkikh, E. A. Tarasenko, L. I. Moskvicheva, S. A. Orlov, A. A. Tryakin, A. V. Vorobeva, O. A. Beneslavskaya, V. I. Makarova, E. A. Putilina, S. A. Utkin. “Off-label” drugs: legal problems and socio-economic aspects of application practice. Pharmacy & Pharmacology 2023; 11(2): 149 doi: 10.19163/2307-9266-2023-11-2-149-160
|